Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma

Pemigatinib is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR)1–3 with efficacy in patients with previously treated, advanced/metastatic cholangiocarcinoma (CCA) with FGFR2 alterations. A previously developed population pharmacokinetic (PK) model of pemigatinib was re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xiaohua, Akil, Ayman, Ndi, Andre, Ji, Tao, Liu, Xiang, Lovern, Mark, Chen, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681497/
https://www.ncbi.nlm.nih.gov/pubmed/37969064
http://dx.doi.org/10.1002/psp4.13064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681497/
https://www.ncbi.nlm.nih.gov/pubmed/37969064
http://dx.doi.org/10.1002/psp4.13064

Ejemplares similares